2020-043 – SHP2 Inhibitors for Cancer Therapy

SHP2 is a protein phosphatase that regulates the RAS pathway that plays a central role in cancer, especially pancreatic, lung, breast, leukemia, melanoma, and ovarian cancer. SHP2 inhibitors have demonstrated high activity in preclinical studies. KSU researchers have discovered new SHP2 inhibitors that have demonstrated significant activity against multiple cancer cell lines. These SHP2 inhibitors are chemically different from other SHP2 inhibitors described in the research and patent literature. They show activity against non-small cell lung cancer, glioblastoma, renal cancer, breast cancer cell lines with GI50 = 1-4 µM. They also show specific cytotoxic activity against melanoma cell lines at 10 µM. Cell cytotoxicity assays were performed by the National Cancer Institute. Caronda Moore caronda@ksu.edu 785-532-1366